Group 1 - The board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. held its third meeting of the fourth session on August 26, 2025, with all seven directors present [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's operational status without any false records or omissions [1][2] - The board also approved amendments to the company's articles of association, eliminating the supervisory board and transferring its powers to the audit committee of the board [2][3] Group 2 - The board approved revisions to internal management systems to enhance corporate governance and compliance with relevant laws and regulations [3][4] - A cash dividend distribution plan for the first half of 2025 was proposed, subject to approval at the upcoming shareholder meeting [4][5] - The board scheduled the second extraordinary general meeting of shareholders for September 15, 2025, to discuss the proposed amendments and dividend plan [4][5]
泓博医药: 董事会决议公告